Highlights Delcath Systems, Inc.

Equities

DCTH

US24661P8077

Real-time Estimate Cboe BZX Other stock markets 11:27:52 2024-05-07 am EDT			5-day change	1st Jan Change
5.805 ^USD	+0.61%		+10.58%	+38.22%

May. 06	Delcath Systems Says Phase 3 Data on Hepzato Kit Published in Oncology Journal	MT
May. 06	Delcath Systems, Inc Announces Publication of Results from Pivotal FOCUS Study in Metastatic Uveal Melanoma Patients treated with HEPZATO KIT	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Delcath Systems Says Phase 3 Data on Hepzato Kit Published in Oncology Journal	May. 06	MT
Delcath Systems, Inc Announces Publication of Results from Pivotal FOCUS Study in Metastatic Uveal Melanoma Patients treated with HEPZATO KIT	May. 06	CI
Delcath Systems Amends Supply, Manufacturing Agreement With Synerx Pharma, Mylan Teoranta for Melphalan Hydrochloride	Apr. 26	MT
Earnings Flash (DCTH) DELCATH SYSTEMS Reports Q4 Revenue $539,000, vs. Street Est of $550,000	Mar. 26	MT
Delcath Systems, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Delcath Systems, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 26	CI
Delcath Systems, Inc. Announces Healthcare Setting Locator for HEPZATO? KIT (melphalan/Hepatic Delivery System)	Feb. 22	CI
Delcath Systems Receives Permanent J-Code for HEPZATO? (melphalan/Hepatic Delivery System) Effective April 1, 2024	Jan. 31	CI
Delcath Systems Launches Hepzato Kit in US for Treatment of Metastatic Uveal Melanoma	Jan. 16	MT
Delcath Systems Announces U.S. Launch and First Commercial Treatment Utilizing Hepzato Kit?	Jan. 16	CI
Earnings Flash (DCTH) DELCATH SYSTEMS Posts Q3 Revenue $434,000	Nov. 13	MT
Delcath Systems, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Delcath Systems Secures $35 Million Funding Linked to FDA Approval of HEPZATO KIT; Shares Rise	23-09-01	MT
Delcath Systems Says FDA Approved HEPZATO KIT for Metastatic Uveal Melanoma	23-08-15	MT
Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal Melanoma	23-08-14	CI
Earnings Flash (DCTH) DELCATH SYSTEMS Reports Q2 Revenue $495,000, vs. Street Est of $0.7M	23-08-09	MT
Delcath Systems, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Delcath Systems, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-22	CI
Delcath Systems, Inc. Provides Preliminary Earnings Guidance for the First Quarter Ended March 31, 2023	23-05-12	CI
Delcath Systems Q4 Net Loss Widens, Revenue Drops	23-03-27	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Delcath Systems, Inc.

Equities

DCTH

US24661P8077

Highlights

Filters